secwatch.observer — SEC 8-K summary
======================================

Issuer:     Spyre Therapeutics, Inc. (SYRE)
CIK:        0001636282
Form:       8-K
Filed at:   2023-06-23T23:59:59+00:00
Accession:  0001193125-23-173242
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.85
Item codes: 1.01, 5.03, 2.01, 3.02, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aeglea BioTherapeutics completes acquisition of Spyre Therapeutics, raises $210M in PIPE financing
--------------------------------------------------------------------------------

- Aeglea issued 13,013,636 common shares and 364,889 Series A Preferred shares to Spyre stockholders.
- Company raised $210M via PIPE sale of 721,452 Series A Preferred shares to accredited investors.
- Appointed Cameron Turtle as COO; Peter Harwin, Tomas Kiselak, and Michael Henderson as new directors.
- Series A Preferred stock is non-voting, convertible into 1,000 common shares, subject to stockholder approval.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1636282/000119312523173242/0001193125-23-173242-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1636282/000119312523173242/d433690d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-173242

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer